Biolex Therapeutics Inc., of Pittsboro, N.C., filed for bankruptcy liquidation, according to its partner OctoPlus N.V. The company aimed to make a better interferon for hepatitis C virus (HCV), and to that end burned through $185 million in venture capital since it was founded in 1997.